Prescription drug · ANDA
fenofibrate NDC 71335-2413
Fenofibrate 145 mg/1 · Tablet · Oral · Bryant Ranch Prepack
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71335-2413-1 | 71335241301 | 30 TABLET in 1 BOTTLE (71335-2413-1)Marketed from Oct 11, 2024 | |
| 71335-2413-2 | 71335241302 | 90 TABLET in 1 BOTTLE (71335-2413-2)Marketed from May 29, 2024 | |
| 71335-2413-3 | 71335241303 | 28 TABLET in 1 BOTTLE (71335-2413-3)Marketed from Jan 31, 2025 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- fenofibrate
- Generic name (nonproprietary)
- fenofibrate
- Active ingredients
- Fenofibrate — 145 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Bryant Ranch Prepack
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 211122
- Marketing start
- Listing expires
- Identifiers
- Product ID 71335-2413_aeee81bb-b8cf-4b57-bc85-813fcc74c79dSPL ID aeee81bb-b8cf-4b57-bc85-813fcc74c79dSPL set ID 6c681270-fe04-4bd8-9fde-98e87ded9b83RxCUI 477560UNII U202363UOS
- Pharmacologic class
- Peroxisome Proliferator Receptor alpha Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N471335241301followed by a unit qualifier and the quantityPackage 71335-2413-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Fenofibrate tablets are peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ). 1.1 Primary Hypercholesterolemia or Mixed Dyslipidemia Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total choleste…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 211122
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| fenofibrate | Fenofibrate 48 mg/1 | TabletOral | Leading Pharma, LLC | 69315-287 |
| fenofibrate | Fenofibrate 145 mg/1 | TabletOral | Leading Pharma, LLC | 69315-288 |
| fenofibrate | Fenofibrate 48 mg/1 | TabletOral | Laurus Labs Limited | 42385-950 |
| fenofibrate | Fenofibrate 145 mg/1 | TabletOral | Laurus Labs Limited | 42385-951 |
| fenofibrate | Fenofibrate 145 mg/1 | TabletOral | NuCare Pharmaceuticals,Inc. | 68071-1712 |